Celltrion Inc. said it would acquire Iqone Healthcare Switzerland SA in the fourth quarter of 2024 for about ₩30 billion (US$21.34 million) to expand its European business. “This move represents a strategic shift in our growth strategy,” Taehun Ha, Celltrion vice president and Europe head, said in a statement Nov. 15.
China’s National Medical Products Administration (NMPA) has accepted Ascentage Pharma Group Corp. Ltd.’s NDA for its in-house-developed Bcl-2 selective inhibitor, lisaftoclax (APG-2575), which could be the first domestically approved Bcl-2 inhibitor in China and the second global approval.
Many studies have linked the presence of specific bacteria to various diseases. But a general overgrowth of gut bacteria can be a symptom of different conditions, including colorectal cancer and inflammatory bowel disease. A study counting gut microbiome proposes that microbial load, rather than the disease, could explain the presence of certain pathogens.
Arkuda Therapeutics Inc. has patented new fused tricyclic mucolipin-1 (MCOLN1; TRPML1) blockers reported to be useful for the treatment of cancer, liver diseases, amyotrophic lateral sclerosis, cardiovascular disorders, frontotemporal dementia, Alzheimer’s, Huntington’s and Parkinson’s disease.
Hangzhou Synrx Therapeutics Biomedical Technology Co. Ltd. recently presented the development and characterization of a novel PARG inhibitor, SYN-608, for the potential treatment of tumors with/without homologous recombination deficiency (HRD).
Tumor cell survival is dependent on phosphate homeostasis, which requires high amounts of energy. Researchers have demonstrated that the silencing of xenotropic and polytropic retrovirus receptor 1 (XPR1) led to reduced tumor growth in an ovarian cancer cell line xenograft, and similar vulnerability was found in lung cancer.
Hepatocellular carcinoma (HCC) is the most common type of liver cancer, with a 5-year survival rate of 18%. Glypican-3 (GPC3) is a protein with high expression in HCC but not in healthy tissue, making it an interesting target for therapy.
Researchers from Bright Biologics LLC presented the discovery and preclinical characterization of a novel bispecific anti-Her2/anti-Trop2 antibody-drug conjugate (ADC), BB-201.
Researchers from Naya Biosciences Inc. and collaborators presented preclinical data on NY-303, a natural killer (NK) cell engager bispecific antibody targeting both GPC3 and NKp46. NKp46 is a cell surface receptor involved in NK cell activation and the elimination of target cancer cells.
RSS
